National Institute of Mental Health (NIMH)
Background: Researchers have developed a new radioactive tracer (11C-ARMI). A tracer is a drug that attaches itself to other chemicals in the body and lights up so that the chemicals can be seen in imaging scans. The new tracer may be able to help them with many diseases, such as Alzheimer s disease and Parkinson s disease. Researchers want to test the new tracer in healthy people. Objective: To test a new tracer (11C-ARMI) during imaging scans of the brain and body in healthy people. Eligibility: Healthy people aged 18 years and older. They must have been screened under protocols 01-M-0254 or 17M0181. Design: All participants will have a positron emission tomography (PET)/computed tomography (CT) scan. Before the scan, they will have blood and urine tests and a test of their heart function. The tracer will be given through a tube attached to a needle inserted into a vein in the arm. They will lie on a padded bed that fits inside a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body. Some participants will have a PET/CT scan of their whole body. They will need only 1 visit. Some participants will have a PET/CT scan of only their brain. They will have up to 2 visits. On the second visit, they will have a magnetic resonance imaging (MRI) scan of the brain. For the MRI, they will lie on a table that slides into a cylinder. The MRI uses magnetic fields to create images of the inside of the body. Participants will receive a follow-up call to check on their well-being after their PET/CT scans.
Study Description: This study is intended to provide information on the novel 11C-ARMI radioligand and its ability to localize and measure Alpha-1A Adrenoreceptor (alpha-1A AR) in the brain and body of healthy volunteers. Objectives: Primary Objective: To study the brain uptake of 11C-ARMI and perform kinetic modeling of 11C-ARMI in healthy volunteers. Secondary Objectives: To study brain retest variability and reliability, biodistribution, and dosimetry of 11C-ARMI in healthy volunteers. Endpoint: Primary Endpoint: For both objectives, the primary endpoint is receptor density measure…
* INCLUSION CRITERIA: 1. Aged 18 years or older. 2. Must have undergone a screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants or 17M0181 Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies. 3. Be healthy based on medical history, physical examination, and laboratory testing. 4. Able to understand and willingness to provide informed consent. 5. Willingness to complete all study procedures including MRI tests. 6. Have had their radial artery pulse checked for the pr…
Injected IV followed by PET scanning